Renal Cancer - Results from #1260

CDCA3 Predicts Poor Prognosis and Affects CD8+ T Cell Infiltration in Renal Cell Carcinoma. October 19, 2022

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. October 18, 2022

Low-grade oncocytic tumor of the kidney is characterized by genetic alterations of TSC1, TSC2, MTOR, or PIK3CA and consistent GATA3 positivity. October 18, 2022

Analysis of surgical outcomes in 102 patients with renal cell carcinoma with venous tumor thrombus: A retrospective observational single-center study. October 17, 2022

N6-methyladenosine long non-coding RNAs reveal novel tool to implicate overall survival and immune microenvironment in renal clear cell carcinoma. October 17, 2022

Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity. October 14, 2022

Identification of a combined lncRNA prognostic signature and knockdown of lncRNA MANCR to inhibit progression of clear cell renal cell carcinoma by bioinformatics analysis. October 14, 2022

Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial. October 13, 2022

Percutaneous thermal ablation for cT1 renal mass in solitary kidney: A multicenter trifecta comparative analysis versus robot-assisted partial nephrectomy. October 13, 2022

A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. October 12, 2022

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis. October 12, 2022

Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre. October 11, 2022

Role of ultra-high b-value DWI in the imaging of hereditary leiomyomatosis and renal cell carcinoma (HLRCC). October 11, 2022

Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma October 10, 2022

Nivolumab plus Ipilimumab plus Cabozantinib Triplet Combination for Patients with Previously Untreated Advanced Renal Cell Carcinoma: Results from a Discontinued Arm of the Phase III CheckMate 9ER Trial October 10, 2022

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma. October 10, 2022

Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study. October 10, 2022

miR-21-5p/PRKCE axis implicated in immune infiltration and poor prognosis of kidney renal clear cell carcinoma. October 7, 2022

Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes. October 7, 2022

Associations between body composition features and clinical outcomes in metastatic clear cell renal cell carcinoma patients treated with immune checkpoint blockade. October 6, 2022

Page 64 of 456